(6R)-2,6-Diamino-4,5,6,7-Tetrahydrobenzothiazole

Preparation of the (6R)-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole enantiomer as a pharmaceutical secondary reference standard for pramipexole dihydrochloride monohydrate impurity profiling necessitates rigorous handling to prevent racemisation induced by ambient moisture and elevated laboratory temperatures. The free base is hygroscopic and undergoes slow amine-carbamate equilibrium with atmospheric CO₂; therefore, standard operating protocols at contract analytical laboratories mandate that the bulk reference lot be subdivided into single-use amber vials inside a glovebox purged with dry nitrogen (<10 ppm H₂O content) and stored at –20 ± 5 °C over freshly activated 4 Å molecular sieves. When preparing the system suitability solution, the compound is spiked into pramipexole dihydrochloride monohydrate working standard at a mass fraction of 0.10% to 0.15% (w/w), precisely weighed on a microbalance (readability 0.001 mg) and dissolved in a diluent composed of acetonitrile and aqueous triethylamine-phosphate buffer (pH 3.0) under continuous magnetic stirring for 30 min to guarantee complete dissolution. The downstream analytical methodology is a pharmacopoeial normal-phase chiral HPLC procedure using an immobilised amylose tris-(3,5-dimethylphenylcarbamate) column (typically 250 × 4.6 mm, 5 μm particle size) thermostatted at 25 °C, with a mobile phase of n-hexane, ethanol, and diethylamine (70:30:0.1, v/v/v) delivered isocratically at 1.0 mL/min and UV detection at 262 nm. The acceptance criterion for resolution between the (R)- and (S)-enantiomer peaks is >3.0, and the tailing factor for the primary analyte must remain within 0.8 to 1.5 as per USP general chapter <621>. The terminal deliverable is a certified reference material batch accompanied by a certificate of analysis compliant with ISO 17034 and ISO/IEC 17025, quantifying the assigned purity on the anhydrous, solvent-free basis via mass balance corrected for organic impurities (HPLC area normalisation ≥99.5%), residual solvents (headspace GC, reference ICH Q3C(R8)), water content (Karl Fischer coulometry, limit ≤0.20%), and residue on ignition.

Industrial production trains that valorise the (6R)-isomer as a recycle stream into (S)-pramipexole dihydrochloride monohydrate rest on a dynamic deracemization sequence preceded by transient amine protection. In a representative campaign executed in a 500-L glass-lined reactor with bottom drain and overhead reflux condenser, the crude (6R)-diamine free base (~85% chiral purity) is charged together with di-tert-butyl dicarbonate (2.20–2.35 molar equivalents) in anhydrous tetrahydrofuran under an argon sweep at 0 to 5 °C, yielding the N,N′-di-Boc derivative. The protection step carries a patent-defined processing risk: water ingress above 500 ppm triggers premature opening of the benzothiazole ring via carbamate hydrolysis, so the tetrahydrofuran is pre-distilled over sodium-benzophenone ketyl and the reactor headspace is maintained at a dew point below –40 °C. After aqueous workup and crystallisation from n-heptane/toluene (4:1 v/v), the di-Boc intermediate obtains a chemical purity exceeding 99.0% by area. Oxidative deracemization is performed in a separate 300-L enamel-lined vessel utilising a 2-azaadamantane N-oxyl (AZADO) catalyst at 1.0 mol% loading relative to substrate, together with a terminal oxidant system of sodium hypochlorite (12.5% active chlorine) buffered by sodium bicarbonate (5.0 equiv) and potassium bromide (0.15 equiv) in a dichloromethane/water biphasic mixture at –5 to 0 °C. The transient imine intermediate is trapped in situ by a chiral ruthenium–diamine complex formulated with RuCl[(R,R)-TsDPEN](mesitylene) (0.05 mol%) and formic acid–triethylamine (5:2 molar ratio) as the hydrogen source, effecting asymmetric transfer hydrogenation to the (S)-di-Boc precursor. The following table summarises the impact of key process variables on the enantioselectivity of the transfer hydrogenation stage, derived from GMP pilot-scale qualification runs:

*TEAF: triethylammonium formate buffer. After chiral purity verification by the pharmacopoeial HPLC method described previously, the (S)-di-Boc intermediate is deprotected in methanolic hydrogen chloride (3.0 M, 20 L/kg substrate) at 40 ± 2 °C for 5 h and crystallised as the dihydrochloride monohydrate salt from isopropanol/water (95:5 v/v). The final API is discharged into a Guedu-type vacuum agitated dryer and dried at 45 °C and 10 mbar until loss on drying falls below 4.5%. The entire campaign operates under ICH Q7 active pharmaceutical ingredient GMP guidelines, with critical quality attributes aligned to Ph. Eur. monograph 2416 and USP Pramipexole Dihydrochloride Monograph. This recycle pathway reduces the overall net mass intensity by 1.8 kg of raw materials per kilogram of final product when benchmarked against purely chiron-pool-based routes.

Covalent immobilisation of the enantiopure diamine onto epoxide-activated macroporous silica gel furnishes a brush-type Pirkle chiral stationary phase (CSP) suitable for the direct enantiomeric separation of non-derivatised arylpropionic acid NSAIDs under reversed-phase conditions. The preparative coupling is carried out in a 20-L rotary evaporator flask charged with 1.0 kg of 3-glycidyloxypropyl-functionalised silica (particle size 5 μm, pore diameter 100 Å, carbon loading 8.5%) and a solution of the (6R)-diamine (0.12 kg, 0.84 mol) in anhydrous toluene (8.0 L) containing 1 mol% ytterbium(III) triflate as a mild Lewis-acid promoter. The slurry is rotated slowly (30 rpm) at 85 °C for 20 h, after which the modified silica is filtered through a sintered-glass Buchner funnel (porosity 4), washed sequentially with toluene, methanol, and acetone, and dried under vacuum at 60 °C for 16 h. Elemental nitrogen analysis by the Dumas method indicates a ligand surface coverage of 0.41 mmol/m². The dry phase is slurry-packed at 450 bar into a 250 × 10 mm semi-preparative HPLC column hardware using slurry solvent isopropanol/chloroform (50:50) and packing solvent methanol at a flow rate of 15 mL/min. The resulting column is evaluated according to the column performance test protocol described in appendix E of the manufacturer’s quality manual, with the critical parameters summarised in the following table:

The finished column is stored in isopropanol and shipped with a certificate of compliance referencing the relevant clauses of ISO 9001:2015 and the testing methods stipulated in USP general chapter <621>. The CSP exhibits a known incompatibility with mobile phases containing more than 5% triethylamine, which promotes gradual aminolysis of the residual glycidyl ether anchors and causes a progressive decrease in retention factor.

The carbon-11 labelled derivative of the (6R)-diamine scaffold is prepared in a hot cell for positron emission tomography (PET) tracer development targeting the high-affinity state of the dopamine D2 receptor. The radiochemical synthesis proceeds via N-[¹¹C]methylation of the free base using [¹¹C]methyl iodide produced in a Cyclotron (18 MeV proton beam on a ¹⁴N₂/H₂ target) and trapped in the precursor solution comprising the (6R)-diamine (0.5–1.0 mg) and sodium hydride (2.0 equivalents) in anhydrous dimethylformamide (300 μL). The labelling reaction is conducted at 80 °C for 5 min, followed by semi-preparative HPLC purification on a reverse-phase C18 column with 0.1% trifluoroacetic acid in acetonitrile/water. The terminal product, formulated as a sterile, apyrogenic solution in 0.9% sodium chloride containing <10% ethanol, falls under the regulatory purview of local radiopharmacy legislation and the European Pharmacopoeia general monograph 0125 on radiopharmaceutical preparations. The mean decay-corrected radiochemical yield is 28% (n=6), with the molar activity exceeding 370 GBq/μmol at end of synthesis, satisfying the threshold for D2 receptor imaging without pharmacological mass effects. The synthesis module is sterilised-in-place with 6% hydrogen peroxide vapour prior to each batch, and a bubble-point integrity test (fluid: water, pressure 3.5 bar) is performed on the sterilising-grade 0.22 μm filter before product release. The application is strictly limited to preclinical and clinical research supply under an authorised radiopharmaceutical Manufacturer’s/Importer’s authorisation, and the specification data are reported in accordance with the EANM guidelines for Good Practice in the Preparation of Radiolabelled Compounds.